Page 11 - Stefan Oschmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck agrees $1 billion deal with Debiopharm for head and neck cancer drug

Germany's Merck KGgA said on Monday it has agreed to pay Swiss biotech Debiopharm up to 900 million euros ($1.08 billion) to develop and commercialise Xevinapant for head and neck cancer. Under the terms of the licensing deal, Merck will pay Debiopharm 188 million euros upfront and has agreed to further regulatory and commercial milestones worth up to 710 million euros, as well as royalties. "This late-stage asset complements our Healthcare pipeline, which will be one of Merck's key growth drivers in the coming years," Chief Executive Stefan Oschmann said in a statement.

Head and neck cancerStefan oschmannதலை மற்றும் கழுத்து புற்றுநோய்

UCB Full Year Report 2020: UCB - sustaining growth, now and into the future (2)

Roch Doliveux informed the Board that, for personal reasons, he will not be candidate for a further renewal.

Roch doliveuxViviane mongesStefan oschmannEngage therapeuticsGeneral meetingAlbrecht de graeveAnnual general meetingஈடுபடுங்கள் சிகிச்சைஜநரல் சந்தித்தல்ஆண்டு ஜநரல் சந்தித்தல்

UCB Full Year Report 2020: UCB - sustaining growth, now and into the future

UCB Full Year Report 2020: UCB - sustaining growth, now and into the future
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesRegion flamandeBruxelles capitalePierre gurdjianViviane mongesRoche genentechJean christophe tellierStefan oschmannAlice dautrySusan gasserJonathan peacockRoch doliveuxMazars bedrijfsrevisorenWaterhouse cooper pwAssembly onDrug administration

IP strategy to safeguard R&D investment becomes secondary issue for big pharma

IP strategy to safeguard R&D investment becomes “secondary issue” for big pharma Delay in vaccine production requires collaboration amongst drug makers to be prioritised by Leanna Reeves - February 24, 2021 Big pharma is urged to put IP strategy aside – typically used to protect their R&D investment in the long-term – due to delays in Covid-19 vaccine production calling for greater collaboration amongst drug makers, according to Adrian Tombling, partner and patent attorney at Withers & Rogers. “At the moment, pharma companies are driven by the urgent need to help save lives by vaccinating as many people as possible, as quickly as possible,” Tombling said in an email.

Stefan oschmannBiontech covidWithers rogersAdrian tomblingவாடிவிடும் ரோஜர்ஸ்

BioNTech secures deals for lipids needed in vaccine

BioNTech secures deals for lipids needed in vaccine
thechemicalengineer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thechemicalengineer.com Daily Mail and Mail on Sunday newspapers.

Baden wubergChristian kullmannStefan oschmannBiontech covidExecutive boardநிர்வாகி பலகை